文献速递胸部肿瘤

新辅助PD-1/PD-L1阻断联合化疗治疗临界可切除及不可切除III期非小细胞肺癌

Neoadjuvant PD-1 and PD-L1 Blockade With Chemotherapy for Borderline Resectable and Unresectable Stage III Non-Small Cell Lung Cancer.
PubMed 文献 · JAMA Oncol · 2025-01-01

这项多中心队列研究分析了2018年2月至2024年1月在美国和意大利学术及三级医疗中心接受新辅助PD-1/PD-L1抑制剂联合化疗的112例T4和/或N2-N3期III期NSCLC患者,结果显示84例(75.0%)接受手术切除,pCR率29.0%,主要病理缓解率42.2%,全部切除患者中位EFS为52.6个月。

要点

  • 112例III期NSCLC患者中84例(75.0%)接受手术切除,pCR率29.0%(24/83),主要病理缓解率42.2%(35/83)。
  • PD-L1表达≥50%且高肿瘤突变负荷患者pCR率最高(4/9,44.4%;P=0.03)。
  • 全部切除患者中位EFS为52.6个月(95%CI 27.8至未达到),pCR患者EFS显著更长(未达到 vs 27.8个月;P<0.001)。

核心结论

  • 新辅助PD-1/PD-L1阻断联合化疗在T4和/或N2-N3期III期NSCLC中取得较高的病理缓解率和手术切除率,为临界可切除或不可切除NSCLC提供了一种可行的治疗选择,但需通过前瞻性研究进一步验证。

研究设计与样本

  • 多中心队列研究,分析2018年2月至2024年1月在美国和意大利学术及三级医疗中心接受新辅助PD-1/PD-L1抑制剂联合铂类化疗的112例III期NSCLC且T4和/或N2-N3受累患者。

主要发现

  • 112例患者中58例(51.8%)为女性,中位(范围)年龄66(41-84)岁。
  • 84例(75.0%)接受手术切除,pCR率29.0%(24/83例有最终病理),主要病理缓解率42.2%(35/83)。
  • PD-L1表达≥50%且高肿瘤突变负荷患者pCR率最高(4/9,44.4%;P=0.03)。
  • KRAS/STK11或KRAS/KEAP1共突变与缺乏pCR相关。
  • 单站或多站N2/N3疾病患者病理结局相当。

临床怎么用

  • 原文结论认为该方案为临界可切除或不可切除NSCLC提供了一种可行的治疗选择,但需通过前瞻性研究进一步验证。

局限性

  • 原文结论指出该方案需通过前瞻性研究进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Patients with borderline resectable or unresectable stage III non-small cell lung cancer (NSCLC) with T4 and/or N2-N3 involvement face limited treatment options and poor outcomes. Neoadjuvant chemoimmunotherapy has shown promise in improving resectability and pathological responses. OBJECTIVE: To evaluate the efficacy of neoadjuvant programmed cell death 1 protein (PD-1) or programmed cell death 1 ligand 1 (PD-L1) blockade combined with chemotherapy in enhancing surgical outcomes and pathological responses in patients with T4 and/or N2-N3 stage III NSCLC. DESIGN, SETTING, AND PARTICIPANTS: This multicenter cohort study analyzed data from patients treated between February 2018 and January 2024 with neoadjuvant PD-1/PD-L1 inhibitors plus chemotherapy at academic and tertiary care centers across the US and Italy. Pathological and survival outcomes were assessed. Patients with stage III NSCLC and T4 and/or N2-N3 involvement were included. Data were collected from February 2018 to January 2024. EXPOSURES: Neoadjuvant PD-1/PD-L1 blockade combined with platinum-based chemotherapy. MAIN OUTCOMES AND MEASURES: Pathological complete response (pCR), major pathological response, surgical resectability, and event-free survival (EFS). RESULTS: Of 112 patients, 58 (51.8%) were female, and the median (range) age was 66 (41-84) years. A total of 84(75.0%) underwent surgical resection, achieving a pCR rate of 29.0% (24 of 83 with available final pathology) and a major pathological response rate of 42.2% (35 of 83). Patients with both PD-L1 expression of 50% or more and high tumor mutational burden achieved the highest pCR rate (4 of 9 [44.4%]; P = .03). Conversely, covariants in KRAS/STK11 or KRAS/KEAP1 were associated with lack of pCR. Patients with single-station or multistation N2/N3 disease exhibited comparable pathological outcomes. The median EFS for all resected patients was 52.6 months (95% CI, 27.8 to not reached), and this was significantly longer in patients with pCR (not reached vs 27.8 months [95% CI, 19.5 to not reached]; P < .001). CONCLUSIONS AND RELEVANCE: In this study, neoadjuvant PD-1/PD-L1 blockade combined with chemotherapy resulted in high pathological response rates and surgical resectability in patients with T4 and/or N2-N3 stage III NSCLC. This approach offers a viable treatment option for patients with borderline resectable or unresectable NSCLC but requires further validation through prospective studies.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Ricciuti B, Fusco F, Cooper A, et al. Neoadjuvant PD-1 and PD-L1 Blockade With Chemotherapy for Borderline Resectable and Unresectable Stage III Non-Small Cell Lung Cancer. JAMA Oncol. 2025. PMID: 40402502. doi:10.1001/jamaoncol.2025.1115

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。